Wikipedia

Search results

08 June, 2016


TURN YOUR PHYSICAL NOTES INTO DIGITAL NOTES

Some people can retain information just as easily via typing as they would when taking notes by hand, but studies have shown that the act of physically writing results in significantly more retention. The best of both worlds is now available in the Equil Digital & Ink Smartpen 2, allowing you to create, edit and share your ideas seamlessly between paper and digital. Now you can pick up your own with a $50 SmartMarker coupon bonus, all for 31% off.
With Equil’s smart stylus, you’re able to write or draw on any number of surfaces, from a Moleskine to a Post-It and everything in between. A wide range of colors and pen tips give you a world of creative options. Your work will instantly appear on your Android, iOS, Mac and Windows devices, with seamless accessibility. You can also save your files and sync to Dropbox, Evernote and iCloud for fully transferrable ideas in your digital ecosystem.


The Equil Digital & Ink Smartpen 2 is your perfect crossover solution. With a bonus $50 SmartMarker Coupon for taking your digital accessibility to even greater heights, your creative workflow flexibility awaits for just $129.95.

Triggers for migraine attacks determined for individual patients



Migraine is the third commonest disorder in the world and ranks sixth amongst more than 300 diseases when it comes to the burden it represents. "Determining the factors that trigger migraine attacks is an important, albeit difficult, step in managing migraine," explains Christian Wöber, head of the section specializing in headaches at MedUni Vienna's Department of Neurology. Reliable indications cannot be obtained merely by asking sufferers but rather they need to keep detailed records in a diary and this data must then undergo complex statistical analysis in order to be able to treat migraine on an individual basis. This is precisely what a new study has shown.
The Headache Working Group at MedUni Vienna is one of the world leaders in researching migraine trigger factors and has aroused the interest of the US start-up "Curelator," which is helping to develop an app for identifying migraine triggers. The collaboration between MedUni Vienna and this company has given rise to a study recently published in the leading journal Cephalalgia.
The study used data from MedUni Vienna to investigate a completely new approach for analyzing migraine trigger factors. For the first time, the trigger factors responsible for a migraine attack were not determined for a collective but rather separately for each individual patient. Wöber: "By analyzing cases on an individual basis, we are able to provide medicine that is tailored to the individual circumstances of each patient. The need for this approach, hitherto uncommon in medical studies, was recently emphasized in the leading journal Nature."
Individual correlation between migraine triggers and attacks
The current study published in Cephalalgia therefore compared the individual case analyses with the overall analysis for the entire study population. The surprising, but at the same time practical, finding: from the population of 326 patients who kept a detailed diary for 90 days, it was possible to identify possible migraine triggers in 87% of sufferers by performing personalized analyses. On average, there were four possible trigger factors for each participant. According to the MedUni Vienna experts, "What was unexpected was that the individual profile of possible trigger factors was extremely variable and was unique in 85% of patients. Each of the 33 migraine trigger factors investigated correlated with migraine attacks, in at least some of the patients." However, in the overall analysis of all 326 volunteers, this was only the case for eight of the factors.
That means: by far the largest proportion of patients were found to have individual triggers, which could not be identified in the overall analysis of all patients. Wöber explains: "For the very first time, this new analysis therefore provides information about the correlation between migraine attacks and a broad spectrum of possible trigger factors for each individual patient and is therefore a step towards personalized migraine management."


SAMSUNG HINTS THE DAWN OF FLEXIBLE ERA OF OF SILICON VALLEY
Samsung flexible display promo (image 001)
Samsung could release a pair of smartphones early next year capable of bending and folding in half “like a cosmetic compact,” without damage, and one of them should be a five-inch model that could be opened to an eight-inch tablet size, Bloomberg reported this morning, citing unnamed people familiar with the project.

Project Valley

Code-named “Project Valley,” the new phones won’t be marketed under the Galaxy S moniker because the South Korean firm does not see these bendable smartphones as its next-generation flagship devices.
Moxi Group, a Chinese company based in Chongqing, has shown off a bendable phone with black and white screens, said Bloomberg.

Samsung Galaxy Flexi?

The two aforementioned phones would use flexible AMOLED screens.
Samsung has been testing the commercial viability of the technology for two years with its multi-sided Galaxy Edge smartphones. The article speculates that commercializing bendable phones would increase Samsung’s chances of securing orders for these screens from Apple.
“This product could be a game-changer if Samsung successfully comes up with a user interface suitable for bendable screens,” said Lee Seung Woo, an analyst at IBK Securities in Seoul.
“Next year is a probable scenario. Their biggest obstacle was related to making transparent plastics and making them durable, which seems resolved by now.”
Here’s Samsung conceptual video created in 2014 which envisions flexible smartphone and tablet concepts for the future.
Samsung may also name the next Note as the “Note 7,” skipping a number in order “to bring it in line with its flagship Galaxy S smartphone range,” one of the sources told Bloomberg.

The future is around the corner

Considering Samsung is said to launch the fully bendable smartphones ahead of Mobile World Congress, which runs from February 27 through March 2, 2017, the South Korean firm hopes to steal some of Apple’s thunder.
Next year, Apple is said to release a tenth-anniversary ‘iPhone 8’ which should switch to AMOLED screens and may even adopt an edge-to-edge, bezel-less appearance that would have the Home button, Touch ID, the front-facing camera and sensors all integrated into the display itself.

VIRTUAL REALITY : THE HEALING REALITY

A virtual reality  experience transforms the user into a 74-year-old named Alfred in order to see his perspective as a medical patient.
Credit: Carrie Shaw
Imagine sitting across from your doctor.
He's speaking to you, but you can't hear him clearly. There's a large black smudge where his face should be, so you're unable to really read his lips. What he's saying is important, so you lean in. But you're frustrated as you struggle to understand what's going on.
You're experiencing life through the eyes of a 74-year-old patient named Alfred -- seven minutes in the shoes of an elderly man whose audiovisual impairments are misdiagnosed as cognitive ones -- and a story that students across many disciplines have worked together to create.
A virtual reality experience transforms the user into a 74-year-old named Alfred in order to see his perspective as a medical patient.
"[We're] trying to portray different kinds of medical conditions, sensory changes from the first-person perspective of a patient," said Carrie Shaw, a master's student in biomedical visualization and content creator of the case study titled, "We Are Alfred." The project was the focus of Shaw's research this year. It won first place in the Art/Design/Humanities & Social Sciences Category among graduate student projects at the UIC Research Forum, as well as the Vesalius Trust Scholarship Award.
Their goal was to craft an interactive, experiential product that could be used for curriculum in geriatrics -- the health and care of elderly people -- because of predicted growth in future U.S. aging populations and a disconnect between patients and the students or doctors who treat them.
"[Medical students] are usually in their early 20s and not experiencing those kinds of challenges yet, so we decided to create something that would give them the experience of what it might be like to go through the aging process," Shaw said.
Users experience that with some headphones and the Oculus Rift Development Kit 2, a headset that can immerse them into a 360-degree virtual reality experience. The headset also includes a Leap Motion device that tracks and projects user's hands in the story to make them feel like they're Alfred.
Becoming Alfred helps users empathize with and better understand elderly patients.
"The project is focusing on comfort," said Eric Swirsky, clinical assistant professor of biomedical and health information sciences and a faculty adviser for the project. "It's not curing, it's not curative, it's not even treatment-oriented. It's about comforting and understanding where the patient is so that you can be with him."
The group started with Alfred .5, the first iteration of the project. The prototype had a completely virtual environment. But after tests, trials, discussion and input from expert geriatricians, the second iteration was refocused to include graphic elements, real people and live scenes -- a redesigned interactive cinema on an almost zero-dollar budget.
"[Interactive cinema] is a kind of marriage of directing for film and directing for theater because you're directing a 360-degree space where the user has the freedom to look wherever they want," said the film's director, Ryan Lebar, a student collaborator from the University of North Carolina School of the Arts.
The live-action story includes six scenes: "Happy Birthday Song," "Day Dream," "Wine Spill," "Waiting Room," "Taking the Cognitive Test" and "Follow Up With the Doctor."
UIC engineering students Thomas Leahy and Jakub Borowski used programming techniques and development tools to stitch together footage and add simulations of medical issues such as severe macular degeneration or hearing loss. "There were a lot of different, new technologies that we were trying to integrate together, and I think that was one of the biggest themes of our whole project," said Leahy.
The group did a lot of troubleshooting and used each others' expertise and ideas to solve problems and tackle challenges.
"I think there's just so much strength in diversity," Shaw said. "It speaks to the complexity of life. If you work in one discipline, it's easy to focus in on that one thing, working with yourself, but if you can balance working across a group of people with different ideas and perspectives, what you create winds up looking a little bit more like the things we actually have to deal with in the world."
"They're in the forefront saying, 'Hey this technology is here and we could be doing more with it,'" added Leah Lebowicz, adviser chair for the project and clinical assistant professor for the biomedical visualization program.
"And when we -- people across many disciplines with different expertise -- all get together, we can produce some amazing things. I think that's what made this project so successful."
Other project collaborators included Yoobin Cha, a graduate student in communication; computer science grad students Karen Corda and Abhishek Tripathi; and faculty member Rachel Yudkowsky, associate professor of medical education.

Story Source:
The above post is reprinted from materials provided by University of Illinois at ChicagoNote: Materials may be edited for content and length.

Cite This Page:
University of Illinois at Chicago. "Future geriatricians 'become' Alfred, a 74-year-old patient, using virtual reality." ScienceDaily. ScienceDaily, 18 May 2016. <www.sciencedaily.com/releases/2016/05/160518153418.htm>.

Share This Page:
AddThis Sharing Buttons

20 Best iOS 9.1 – iOS 9 Themes for iPhone

Best iOS 9 themes
Tweaks on a jailbroken iPhone are only half of what a jailbroken device is about. The other half is all about themes that allow you to transform the look and feel of your device.
So today we’re going to take a look at the top 20 themes for iOS 9 for your iPhone. A lot can be told with a single screenshot. You’ll be able to tell whether or not you’d want to check out the theme just by looking at a few icons, so let’s take a look at these top 20 themes!

Indigo


Indigo Winterboard Theme

Veexilum

Veexilum - iOS 9 Theme

Amury

Amury - Winterboard theme
Ace El Cap – $1.99

Ace El Cap

Avier for iOS9

Avier for iOS 9 - Winterboard theme

Flatish

Flatish - Winterboard theme
Jelly 3

Jelly 3 - WinterBoard Theme
Primo

Primo - iOS 9 WinterBoard theme

Insight

Insight - iOS 9 theme

Soft

Soft - WinterBoard theme for iOS 9
Axla 3

Axla 3 - iOS 9 Theme
Aube for iOS9

Aube - Winterboard theme for iOS 9
Flat6

Flat6 - Winterboard theme for iOS 9

Enkel

Enkel - Winterboard theme for iOS 9

Ambre iOS9

Ambre - iOS 9 Theme

FiZiP

FiZiP - WinterBoard theme for iOS 9
Flat 8

Flat 8 - WinterBoard theme for iOS 9Muze 2

Muze 2 - WinterBoard theme for iOS 9
reduxios

reduxios - WinterBoard theme for iOS 9
Irys

Irys - iOS 9 Theme
Glyphs (CJ Glyphs)

Glyphs (CJ Glyphs)

ADHD DRUG CAUSES CARDIAC ARREST 

Use of methylphenidate in children and young people with ADHD is associated with a slightly increased risk of abnormal heart rhythm (arrhythmia) shortly after the start of treatment, suggests research published by The BMJ today.


Though the absolute risk is likely to be low, the researchers say the benefits of methylphenidate "should be carefully weighed against the potential cardiovascular risks of these drugs in children and adolescents."
Methylphenidate is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD), and narcolepsy. It is sold under various trade names, Ritalin being one of the most commonly known.
The cardiac safety of stimulants, which are known to slightly raise blood pressure and accelerate the heart rate, has been hotly debated, but the evidence is conflicting.
So a team of researchers based in Australia, Canada and South Korea set out to measure the cardiac safety of methylphenidate in children and young people with ADHD.
Using the South Korea National Health Insurance Database, they extracted data on 1,224 cHildren and 
cardiac events from a population of 114,647 children and young people aged 17.

Cardiac events included heart rhythm problems (arrhythmias), high blood pressure heart attacks (myocardial infarction), ischemic stroke, and heart failure.

Cases of arrhythmia were statistically significantly more likely to have occurred during the first two months of use compared with periods of non-use, and risk was highest in the first three days of use.
The risk was more pronounced in children with existing congenital heart disease

significant risk of myocardial infarction was observed, though risk increased after the first week of treatment and remained raised for the first two months of continuous treatment.
No increased risk was observed for hypertension, ischemic stroke, or heart failure.
The authors point out that this is an observational study so no firm conclusions can be drawn about cause and effect -- and that their findings should be interpreted with caution. However, the results prompt them to suggest that methylphenidate use might "trigger" the occurrence of arrhythmia in individual patients.
"Methylphenidate exposure in children and young people with diagnosis of ADHD is associated with arrhythmia and potentially with myocardial infarction in specific time periods of use," they write. "With the increased use of drugs for ADHD globally, the benefits of methylphenidate should be carefully weighed against the potential cardiovascular risks of these drugs in children and adolescents."
In a linked editorial, John Jackson, a research fellow at Harvard School of Public Health in Boston, says it is difficult to describe the absolute risk in this type of study, but in the average child, the risk of serious cardiovascular events is extremely small (3 per 100,000 per year) and any absolute increase associated with methylphenidate is also likely to be small.
And he points out that regulatory labeling and treatment guidelines for stimulants recommend caution using these drugs in children with personal or familial history of cardiovascular disease and call for routine monitoring of blood pressure.
"This study underscores the need to consider the severity of ADHD symptoms and the option of non-stimulants for children with high cardiovascular risk and to closely monitor patients for whom stimulants are critical for their wellbeing and development," he concludes.

Genetic risk for type 1 diabetes driven by faulty cell recycling


FULL STORY


Researcher Scott Soleimanpour, M.D., who lives with type 1 diabetes, publishes findings about faulty cell recycling that disrupts the ability of beta cells to regulate blood sugar.
Credit: University of Michigan Health System
Researchers, tackling a modern challenge of diabetes research, have identified a gene believed to disrupt the ability of beta cells to produce insulin resulting in type 1 diabetes.
The loss of beta cell function may be driven by a defect in Clec16a, a gene responsible for getting rid of old mitochondria, the powerhouses of cells, and making room for fresh ones. Healthy mitochondria are crucial to allowing beta cells to produce insulin and control blood sugar levels.
Little has been known about the ways in which many diabetes genes work, but a study published in the journal Cell sheds light on a genetic risk component of type 1 diabetes and a new approach for keeping beta cells strong.
"Preserving beta cells is the top priority in diabetes care," says lead author Scott Soleimanpour, M.D., investigator at the University of Michigan's Brehm Diabetes Research Center. "This new pathway will allow us to focus therapies on preserving healthy mitochondria within the beta cell to treat or prevent both type 1 and type 2 diabetes."
Soleimanpour, an endocrinologist who treats patients at the University of Michigan Health System, has lived with type 1 diabetes for 30 years.
He's made a career of studying diabetes, including a fellowship at Perelman School of Medicine at the University of Pennsylvania where his laboratory work to understand Clec16a began.
Type 1 diabetes is the unpreventable form of diabetes that usually strikes children and young adults. It's less common than type 2 diabetes which is associated with older age and obesity.
Diabetes is diagnosed when the body has an abnormally high level of glucose, or blood sugar. It's believed that in type 1 diabetes, the body's immune system destroys the pancreatic beta cells responsible for making insulin, a hormone the body needs to convert food into energy.
But that model may be changing after studying Clec16a mutations in both animal and human beta cells.
"Scientists are starting to appreciate the importance of beta cells in understanding why type 1 diabetes occurs," says Soleimanpour, a U-M assistant professor of medicine. "Rather than innocent bystanders to a malfunctioning immune system, our research shows beta cells are central players in the disease itself."
TYPE 1 DIABETES ? A CURE IS HIGHLY POSSIBLE 


FULL STORY
Laboratory mouse (stock image). In this study, researchers found that two nuclear receptors play critical roles in the development of TH17 cells, and that by targeting these receptors, they were able to stop autoimmunity from developing in several mouse models, sparing beta cells.
Credit: © mrks_v / Fotolia
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model.
Type I diabetes is a chronic autoimmune disease that occurs when the body's immune system destroys insulin producing pancreatic beta cells, resulting in insulin deficiency and hyperglycemia. Current treatments for type I diabetes focus on controlling blood sugar with insulin therapy and must continue throughout a person's life.
Burris and his research team focused on blocking the autoimmune process that destroys beta cells and leads to diabetes, with the aim of developing therapies that can prevent the illness from developing rather than treating its symptoms.
"None of the animals on the treatment developed diabetes even when we started treatment after significant beta cell damage had already occurred. We believe this type of treatment would slow the progression of type I diabetes in people or potentially even eliminate the need for insulin therapy," said Burris.
Scientists already knew that at least two types of immune "T-cells" contribute to the development of type I diabetes. However, the role of a third type, TH17, remained unclear.
In this study, researchers found that two nuclear receptors play critical roles in the development of TH17 cells, and that by targeting these receptors, they were able to stop autoimmunity from developing in several mouse models, sparing beta cells.
The team blocked the receptors (ROR alpha and gamma t) with SR1001 (a selective ROR alpha and gamma t inverse agonist developed by Burris), significantly reducing diabetes in mice that were treated with it.
These results confirm that TH17 cells likely play a key role in the development of type I diabetes and suggest that the use of drugs that target this cell type may offer a new treatment for the illness.